First pre-competitive project initiated
A key goal of the Milner Therapeutics Consortium is to enable collaborations between Cambridge academics and our Consortium companies using forward-thinking pre-competitive models. We can now announce that the first such project has been established with Ludovic...
New University Enterprise Zone announced
The Milner Therapeutics Institute will form part of a University Enterprise Zone, created through a new government initiative announced today by Universities Minister Chris Skidmore. Research England, part of UK Research and Innovation, today announced 20 new...
Welcome to Pathania group
We are delighted to welcome the group of Manav Pathania (Dept Oncology), who moved into the Milner Institute this month. The Pathania group have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis...
Renewal of Milner Therapeutics Consortium
We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex, AstraZeneca, Ferring, GlaxoSmithKline, J & J Innovation, Pfizer, Shionogi) who are committed to collaboration and...
Cambridge Biotech Week
The Milner Therapeutics Symposium 2019 is part of Cambridge Biotech Week (25-28th June), a festival of events focused on accelerating scientific ideas and facilitating investment and growth for both early and mature companies on the cutting-edge of healthcare and life...
Start Codon announced as new world-class life science accelerator
This innovative new accelerator programme will provide significant funding and support for selected start-ups, with office and lab space in the Milner Research Labs.
